Skip to content
NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Nuvation Bio Inc. NUVB

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$62.9M
▲ 699.0% YoY
$-204.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 62.9M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 62.9 · Net income -204.6
-200M-400M
202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−325 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -338.7%
-2000%-4000%-6000%
202020222025
ROE
FY2025 · ROE -53.2%
-50%-100%
202020222025
Three returns, three denominators.

Each USD of equity lost 53 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks

Total assetsUSD 594.8M
EquityUSD 305.7M
CashUSD 164.1M
Gross debtUSD 52.9M
Net debtUSD -111.2M
Current ratio6.95×

The company holds more cash than debt.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
NUVB, 6-year financial record
Metric 202520242023202220212020
Revenue $B0.10.00.0◌◌◌
Operating income $B−0.2−0.6−0.1−0.1−0.1−0.0
EBITDA $B◌◌◌◌◌◌
Income tax $B0.00.00.00.00.00.0
Net income $B−0.2−0.6−0.1−0.1−0.1−0.0
EPS, diluted $−0.60−2.11−0.35−0.48−0.44−0.43
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %−53.2−106.3−12.0−14.9−18.1−19.4
Shares out B0.340.340.220.220.220.15

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 26 reconciliationsAUDITED

Reconciled in 6 of the 6 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 16 checks were skipped: revenue is not tagged before 2023. 13 checks were skipped: EPS is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2020

Share this section

Download image